A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589
This study is recruiting at 20 US sites in 13 states, according to its ClinicalTrials.gov record last updated .
Summary
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Asthma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 5 to 11 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Research Site · Montgomery, AL
Arizona · 1
- Research Site · Phoenix, AZ
California · 2
- Research Site · Long Beach, CA
- Research Site · San Diego, CA
Georgia · 1
- Research Site · Atlanta, GA
Maryland · 1
- Research Site · Baltimore, MD
Massachusetts · 2
- Research Site · Boston, MA
- Research Site · Boston, MA
Michigan · 1
- Research Site · Detroit, MI
New Jersey · 1
- Research Site · Northfield, NJ
New York · 2
- Research Site · Hawthorne, NY
- Research Site · Staten Island, NY
North Carolina · 1
- Research Site · Chapel Hill, NC
Ohio · 3
- Research Site · Cincinnati, OH
- Research Site · Cleveland, OH
- Research Site · Toledo, OH
Oklahoma · 1
- Research Site · Oklahoma City, OK
Texas · 3
- Research Site · Dallas, TX
- Research Site · Houston, TX
- Research Site · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.